Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

European approval beckons for muscular dystrophy drug

Child in wheelchair (Aldegonde Le Compte/Dreamstime.com)

Ataluren will be available for children aged five years and older whose disease is caused by defects in the dystrophin gene

The first drug of its kind to treat a particular form of Duchenne muscular dystrophy is being recommended for use in the European Union by the European Medicines Agency (EMA).

Ataluren encourages the cell to ignore ‘nonsense mutations’ that gradually cause weakness and loss of muscle function. It will be available for children aged five years and older whose disease is caused by defects in the dystrophin gene. This disorder is estimated to affect around 200 children and young people in the UK.

The EMA’s Committee for Medicinal Products for Human Use initially decided not to approve the drug in January, but reappraised the data following a request from the medicine’s manufacturer, PTC Therapeutics.

The committee decided last Friday (23 May 2014) that there is enough evidence to recommend the drug on the condition that the manufacturer provides it with ongoing results from its clinical trials.

The decision is described as an “important milestone for drug development programmes in Duchenne muscular dystrophy” by Volker Stroub, a neuromuscular researcher at Newcastle University, UK.

Conditional marketing authorisation is an early access mechanism that allows the EMA to recommend authorisation for medicines that address an unmet medical need, even if comprehensive clinical data are not yet available.

The European Commission must approve the recommendation before the drug can be made available in member states.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.11138704

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.